1
|
Rutowicz K, Lüthi J, de Groot R, Holtackers R, Yakimovich Y, Pazmiño DM, Gandrillon O, Pelkmans L, Baroux C. Multiscale chromatin dynamics and high entropy in plant iPSC ancestors. J Cell Sci 2024:jcs.261703. [PMID: 38738286 DOI: 10.1242/jcs.261703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Accepted: 04/29/2024] [Indexed: 05/14/2024] Open
Abstract
Plant protoplasts provide a starting material to induce pluripotent cell masses in vitro competent for tissue regeneration. Dedifferentiation is associated with large-scale chromatin reorganisation and massive transcriptome reprogramming, characterized by stochastic gene expression. How this cellular variability reflects on chromatin organisation in individual cells and what are the factors influencing chromatin transitions during culturing is largely unknown. High-throughput imaging and a custom, supervised image analysis protocol extracting over 100 chromatin features unravelled a rapid, multiscale dynamics of chromatin patterns which trajectory strongly depends on nutrients availability. Decreased abundance in H1 (linker histones) is hallmark of chromatin transitions. We measured a high heterogeneity of chromatin patterns indicating an intrinsic entropy as hallmark of the initial cultures. We further measured an entropy decline over time, and an antagonistic influence by external and intrinsic factors, such as phytohormones and epigenetic modifiers, respectively. Collectively, our study benchmarks an approach to understand the variability and evolution of chromatin patterns underlying plant cell reprogramming in vitro.
Collapse
Affiliation(s)
- Kinga Rutowicz
- University of Zurich, Institute of Plant and Microbial Biology, Plant Developmental Genetics, Switzerland
| | - Joel Lüthi
- University of Zurich, Department of Molecular Life Sciences, Switzerland
| | - Reinoud de Groot
- University of Zurich, Department of Molecular Life Sciences, Switzerland
| | - René Holtackers
- University of Zurich, Department of Molecular Life Sciences, Switzerland
| | - Yauhen Yakimovich
- University of Zurich, Department of Molecular Life Sciences, Switzerland
| | - Diana M Pazmiño
- University of Zurich, Institute of Plant and Microbial Biology, Plant Developmental Genetics, Switzerland
| | - Olivier Gandrillon
- University of Lyon, ENS de Lyon, Laboratory of Biology and Modeling of the Cell, France
| | - Lucas Pelkmans
- University of Zurich, Department of Molecular Life Sciences, Switzerland
| | - Célia Baroux
- University of Zurich, Institute of Plant and Microbial Biology, Plant Developmental Genetics, Switzerland
| |
Collapse
|
2
|
Moore J, Basurto-Lozada D, Besson S, Bogovic J, Bragantini J, Brown EM, Burel JM, Casas Moreno X, de Medeiros G, Diel EE, Gault D, Ghosh SS, Gold I, Halchenko YO, Hartley M, Horsfall D, Keller MS, Kittisopikul M, Kovacs G, Küpcü Yoldaş A, Kyoda K, le Tournoulx de la Villegeorges A, Li T, Liberali P, Lindner D, Linkert M, Lüthi J, Maitin-Shepard J, Manz T, Marconato L, McCormick M, Lange M, Mohamed K, Moore W, Norlin N, Ouyang W, Özdemir B, Palla G, Pape C, Pelkmans L, Pietzsch T, Preibisch S, Prete M, Rzepka N, Samee S, Schaub N, Sidky H, Solak AC, Stirling DR, Striebel J, Tischer C, Toloudis D, Virshup I, Walczysko P, Watson AM, Weisbart E, Wong F, Yamauchi KA, Bayraktar O, Cimini BA, Gehlenborg N, Haniffa M, Hotaling N, Onami S, Royer LA, Saalfeld S, Stegle O, Theis FJ, Swedlow JR. OME-Zarr: a cloud-optimized bioimaging file format with international community support. Histochem Cell Biol 2023; 160:223-251. [PMID: 37428210 PMCID: PMC10492740 DOI: 10.1007/s00418-023-02209-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/16/2023] [Indexed: 07/11/2023]
Abstract
A growing community is constructing a next-generation file format (NGFF) for bioimaging to overcome problems of scalability and heterogeneity. Organized by the Open Microscopy Environment (OME), individuals and institutes across diverse modalities facing these problems have designed a format specification process (OME-NGFF) to address these needs. This paper brings together a wide range of those community members to describe the cloud-optimized format itself-OME-Zarr-along with tools and data resources available today to increase FAIR access and remove barriers in the scientific process. The current momentum offers an opportunity to unify a key component of the bioimaging domain-the file format that underlies so many personal, institutional, and global data management and analysis tasks.
Collapse
Affiliation(s)
- Josh Moore
- German BioImaging-Gesellschaft für Mikroskopie und Bildanalyse e.V., Constance, Germany.
| | | | - Sébastien Besson
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | - John Bogovic
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | | | - Eva M Brown
- Allen Institute for Cell Science, Seattle, WA, USA
| | - Jean-Marie Burel
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | - Xavier Casas Moreno
- Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden
| | | | | | - David Gault
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | | | - Ilan Gold
- Harvard Medical School, Boston, MA, USA
| | | | - Matthew Hartley
- European Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Cambridge, UK
| | - Dave Horsfall
- Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK
| | | | - Mark Kittisopikul
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | - Gabor Kovacs
- Allen Institute for Neural Dynamics, Seattle, WA, USA
| | - Aybüke Küpcü Yoldaş
- European Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Cambridge, UK
| | - Koji Kyoda
- RIKEN Center for Biosystems Dynamics Research, Kobe, Japan
| | | | - Tong Li
- Wellcome Sanger Institute, Hinxton, UK
| | - Prisca Liberali
- Friedrich Miescher Institute for Biomedical Imaging, Basel, Switzerland
| | - Dominik Lindner
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | | | - Joel Lüthi
- Friedrich Miescher Institute for Biomedical Imaging, Basel, Switzerland
| | | | | | - Luca Marconato
- Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
| | | | | | - Khaled Mohamed
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | - William Moore
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | - Nils Norlin
- Department of Experimental Medical Science & Lund Bioimaging Centre, Lund University, Lund, Sweden
| | - Wei Ouyang
- Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden
| | | | - Giovanni Palla
- Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany
| | | | | | - Tobias Pietzsch
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | - Stephan Preibisch
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | | | | | | | - Nicholas Schaub
- Information Technology Branch, National Center for Advancing Translational Science, National Institutes of Health, Bethesda, USA
| | | | | | | | | | | | | | - Isaac Virshup
- Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany
| | - Petr Walczysko
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | | | - Erin Weisbart
- Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Frances Wong
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | - Kevin A Yamauchi
- Department of Biosystems Science and Engineering, ETH Zürich, Zürich, Switzerland
| | | | - Beth A Cimini
- Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | | | | | - Nathan Hotaling
- Information Technology Branch, National Center for Advancing Translational Science, National Institutes of Health, Bethesda, USA
| | - Shuichi Onami
- RIKEN Center for Biosystems Dynamics Research, Kobe, Japan
| | | | - Stephan Saalfeld
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | - Oliver Stegle
- Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
| | - Fabian J Theis
- Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany
| | - Jason R Swedlow
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| |
Collapse
|
3
|
Moore J, Basurto-Lozada D, Besson S, Bogovic J, Bragantini J, Brown EM, Burel JM, Moreno XC, de Medeiros G, Diel EE, Gault D, Ghosh SS, Gold I, Halchenko YO, Hartley M, Horsfall D, Keller MS, Kittisopikul M, Kovacs G, Yoldaş AK, Kyoda K, de la Villegeorges ALT, Li T, Liberali P, Lindner D, Linkert M, Lüthi J, Maitin-Shepard J, Manz T, Marconato L, McCormick M, Lange M, Mohamed K, Moore W, Norlin N, Ouyang W, Özdemir B, Palla G, Pape C, Pelkmans L, Pietzsch T, Preibisch S, Prete M, Rzepka N, Samee S, Schaub N, Sidky H, Solak AC, Stirling DR, Striebel J, Tischer C, Toloudis D, Virshup I, Walczysko P, Watson AM, Weisbart E, Wong F, Yamauchi KA, Bayraktar O, Cimini BA, Gehlenborg N, Haniffa M, Hotaling N, Onami S, Royer LA, Saalfeld S, Stegle O, Theis FJ, Swedlow JR. OME-Zarr: a cloud-optimized bioimaging file format with international community support. bioRxiv 2023:2023.02.17.528834. [PMID: 36865282 PMCID: PMC9980008 DOI: 10.1101/2023.02.17.528834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
A growing community is constructing a next-generation file format (NGFF) for bioimaging to overcome problems of scalability and heterogeneity. Organized by the Open Microscopy Environment (OME), individuals and institutes across diverse modalities facing these problems have designed a format specification process (OME-NGFF) to address these needs. This paper brings together a wide range of those community members to describe the cloud-optimized format itself -- OME-Zarr -- along with tools and data resources available today to increase FAIR access and remove barriers in the scientific process. The current momentum offers an opportunity to unify a key component of the bioimaging domain -- the file format that underlies so many personal, institutional, and global data management and analysis tasks.
Collapse
Affiliation(s)
- Josh Moore
- German BioImaging – Gesellschaft für Mikroskopie und Bildanalyse e.V., Konstanz, Germany
| | | | - Sébastien Besson
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | - John Bogovic
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | | | - Eva M. Brown
- Allen Institute for Cell Science, Seattle, WA, USA
| | - Jean-Marie Burel
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | - Xavier Casas Moreno
- Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden
| | | | | | - David Gault
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | | | - Ilan Gold
- Harvard Medical School, Boston, MA, USA
| | | | - Matthew Hartley
- European Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Cambridge, UK
| | - Dave Horsfall
- Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK
| | | | - Mark Kittisopikul
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | - Gabor Kovacs
- Allen Institute for Neural Dynamics, Seattle, WA, USA
| | - Aybüke Küpcü Yoldaş
- European Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Cambridge, UK
| | - Koji Kyoda
- RIKEN Center for Biosystems Dynamics Research, Kobe, Japan
| | | | - Tong Li
- Wellcome Sanger Institute, Hinxton, UK
| | - Prisca Liberali
- Friedrich Miescher Institute for Biomedical Imaging, Basel, Switzerland
| | - Dominik Lindner
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | | | - Joel Lüthi
- Friedrich Miescher Institute for Biomedical Imaging, Basel, Switzerland
| | | | | | - Luca Marconato
- European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany
| | | | - Merlin Lange
- Chan Zuckerberg Biohub, San Francisco, CA, United States
| | - Khaled Mohamed
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | - William Moore
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | - Nils Norlin
- Department of Experimental Medical Science & Lund Bioimaging Centre, Lund University, Lund, Sweden
| | - Wei Ouyang
- Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden
| | | | - Giovanni Palla
- Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany
| | | | | | - Tobias Pietzsch
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | - Stephan Preibisch
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | | | | | | | - Nicholas Schaub
- Information Technology Branch, National Center for Advancing Translational Science, National Institutes of Health
| | | | | | | | | | | | | | - Isaac Virshup
- Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany
| | - Petr Walczysko
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | | | - Erin Weisbart
- Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
| | - Frances Wong
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| | - Kevin A. Yamauchi
- Department of Biosystems Science and Engineering, ETH Zürich, Switzerland
| | | | - Beth A. Cimini
- Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
| | | | | | - Nathan Hotaling
- Information Technology Branch, National Center for Advancing Translational Science, National Institutes of Health
| | - Shuichi Onami
- RIKEN Center for Biosystems Dynamics Research, Kobe, Japan
| | - Loic A. Royer
- Chan Zuckerberg Biohub, San Francisco, CA, United States
| | - Stephan Saalfeld
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | - Oliver Stegle
- European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany
| | - Fabian J. Theis
- Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany
| | - Jason R. Swedlow
- Divisions of Molecular Cell and Developmental Biology, and Computational Biology, University of Dundee, Dundee, Scotland, UK
| |
Collapse
|
4
|
Deemyad T, Lüthi J, Spruston N. Astrocytes integrate and drive action potential firing in inhibitory subnetworks. Nat Commun 2018; 9:4336. [PMID: 30337521 PMCID: PMC6194108 DOI: 10.1038/s41467-018-06338-3] [Citation(s) in RCA: 64] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Accepted: 08/27/2018] [Indexed: 12/29/2022] Open
Abstract
Many brain functions depend on the ability of neural networks to temporally integrate transient inputs to produce sustained discharges. This can occur through cell-autonomous mechanisms in individual neurons and through reverberating activity in recurrently connected neural networks. We report a third mechanism involving temporal integration of neural activity by a network of astrocytes. Previously, we showed that some types of interneurons can generate long-lasting trains of action potentials (barrage firing) following repeated depolarizing stimuli. Here we show that calcium signaling in an astrocytic network correlates with barrage firing; that active depolarization of astrocyte networks by chemical or optogenetic stimulation enhances; and that chelating internal calcium, inhibiting release from internal stores, or inhibiting GABA transporters or metabotropic glutamate receptors inhibits barrage firing. Thus, networks of astrocytes influence the spatiotemporal dynamics of neural networks by directly integrating neural activity and driving barrages of action potentials in some populations of inhibitory interneurons. Specific types of inhibitory neurons exhibit prolonged, high-frequency barrages of action potentials. Here, the authors show that astrocytes might mediate such barrage firing.
Collapse
Affiliation(s)
- Tara Deemyad
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, 20147, USA.,Department of Neurobiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | - Joel Lüthi
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, 20147, USA.,Institute of Molecular Life Sciences, University of Zürich, Zürich, 8057, Switzerland
| | - Nelson Spruston
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, 20147, USA.
| |
Collapse
|
5
|
de Groot R, Lüthi J, Lindsay H, Holtackers R, Pelkmans L. Large-scale image-based profiling of single-cell phenotypes in arrayed CRISPR-Cas9 gene perturbation screens. Mol Syst Biol 2018; 14:e8064. [PMID: 29363560 PMCID: PMC5787707 DOI: 10.15252/msb.20178064] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
High‐content imaging using automated microscopy and computer vision allows multivariate profiling of single‐cell phenotypes. Here, we present methods for the application of the CISPR‐Cas9 system in large‐scale, image‐based, gene perturbation experiments. We show that CRISPR‐Cas9‐mediated gene perturbation can be achieved in human tissue culture cells in a timeframe that is compatible with image‐based phenotyping. We developed a pipeline to construct a large‐scale arrayed library of 2,281 sequence‐verified CRISPR‐Cas9 targeting plasmids and profiled this library for genes affecting cellular morphology and the subcellular localization of components of the nuclear pore complex (NPC). We conceived a machine‐learning method that harnesses genetic heterogeneity to score gene perturbations and identify phenotypically perturbed cells for in‐depth characterization of gene perturbation effects. This approach enables genome‐scale image‐based multivariate gene perturbation profiling using CRISPR‐Cas9.
Collapse
Affiliation(s)
- Reinoud de Groot
- Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland
| | - Joel Lüthi
- Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.,Systems Biology PhD program, Life Science Zürich Graduate School ETH Zürich and University of Zürich, Zürich, Switzerland
| | - Helen Lindsay
- Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland
| | - René Holtackers
- Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland
| | - Lucas Pelkmans
- Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland
| |
Collapse
|
6
|
Wild D, Lüthi J, Merkle EM. Dear ladies and gentlemen, dear colleagues. Nuklearmedizin 2015. [DOI: 10.1055/s-0037-1616613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
7
|
Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol 2011; 23:1474-81. [PMID: 22003243 DOI: 10.1093/annonc/mdr448] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND The risk of osteoporosis and fracture influences the selection of adjuvant endocrine therapy. We analyzed bone mineral density (BMD) in Swiss patients of the Breast International Group (BIG) 1-98 trial [treatment arms: A, tamoxifen (T) for 5 years; B, letrozole (L) for 5 years; C, 2 years of T followed by 3 years of L; D, 2 years of L followed by 3 years of T]. PATIENTS AND METHODS Dual-energy X-ray absorptiometry (DXA) results were retrospectively collected. Patients without DXA served as control group. Repeated measures models using covariance structures allowing for different times between DXA were used to estimate changes in BMD. Prospectively defined covariates were considered as fixed effects in the multivariable models. RESULTS Two hundred and sixty-one of 546 patients had one or more DXA with 577 lumbar and 550 hip measurements. Weight, height, prior hormone replacement therapy, and hysterectomy were positively correlated with BMD; the correlation was negative for letrozole arms (B/C/D versus A), known osteoporosis, time on trial, age, chemotherapy, and smoking. Treatment did not influence the occurrence of osteoporosis (T score < -2.5 standard deviation). CONCLUSIONS All aromatase inhibitor regimens reduced BMD. The sequential schedules were as detrimental for bone density as L monotherapy.
Collapse
Affiliation(s)
- K Zaman
- Breast Center, CePO, University Hospital, Lausanne.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Genton C, Aebi S. Modeling bone mineral density (BMD) evolution in postmenopausal patients treated by letrozole (L), tamoxifen (T), and sequences of T and L (SAKK 21/07). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
545 Background: Osteoporosis and fractures are long term complications of aromatase inhibitor use in the adjuvant therapy of breast cancer. Early detection of patients (pts) at risk of treatment-induced osteoporosis may allow preventive therapy and selection of the most appropriate endocrine therapy. We developed a statistical model describing the evolution of BMD in pts treated with T, L and sequences of T and L. Methods: Available dual-energy x-ray absorptiometry exams (DXA) of pts treated in trial BIG 1–98 were retrospectively collected from Swiss centers. Treatment arms: A) T for 5 years; B) L for 5 years; C) 2 years of T followed by 3 years of L; and D) 2 years of L followed by 3 years of T. Pts without DXA were used as a control for detecting selection bias. A repeated measures model using the first-order autoregressive covariance structure to allow for different times between DXA was used to model BMD (g/cm2) since trial randomisation. Prospectively defined covariates were considered as fixed effects in a multivariable model using an intention to treat analysis. Covariates at trial randomization were: age, height, weight, race, known osteoporosis, tobacco use, prior bone fracture, prior hormone replacement therapy (HRT), bisphosphonate use and previous neo-/adjuvant chemotherapy (ChT). Results: A total of 247 out of 546 pts had between 1 and 5 DXA; a total of 576 DXA were collected. Arm A contained 67 pts, B 63 pts, C 55 pts and D 62 pts. Median follow-up was 5.8 years. Factors correlated with BMD in the multivariate analysis were weight (0.003/kg, p < 0.0001), height (0.003/cm, p = 0.0083), osteoporosis (-0.130, p < 0.0001), tobacco (current / previously vs. never: -0.057, p = 0.0011 / -0.042, p = 0.0798), previous HRT (0.030, p = 0.0244), ChT (0.032, p = 0.0174), time since endocrine therapy start (-0.009/year, p = 0.0164) and treatment arm (B / C / D vs. A: -0.068, p = 0.0002 / -0.091, p < 0.0001 / -0.064, p = 0.003). Conclusions: Our statistical model describes the BMD evolution for pts treated with L and/or T. All treatment regimens affect BMD. Contrary to expectation, the switch schedule T followed by L does not seem to result in better bone protection compared to L monotherapy. [Table: see text]
Collapse
Affiliation(s)
- K. Zaman
- CEPO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Breast Center, Kantonspital, St. Gallen, Switzerland; Kantonsspital, Aarau, Switzerland; Oncology Institute of Southern Switzerland, Viganello, Lugano, Switzerland; Oncology Hospital, Thun, Switzerland; SAKK Coordinating Center, Bern, Switzerland; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, University Hospital, Bern, Switzerland
| | - B. Thürlimann
- CEPO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Breast Center, Kantonspital, St. Gallen, Switzerland; Kantonsspital, Aarau, Switzerland; Oncology Institute of Southern Switzerland, Viganello, Lugano, Switzerland; Oncology Hospital, Thun, Switzerland; SAKK Coordinating Center, Bern, Switzerland; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, University Hospital, Bern, Switzerland
| | - J. Huober
- CEPO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Breast Center, Kantonspital, St. Gallen, Switzerland; Kantonsspital, Aarau, Switzerland; Oncology Institute of Southern Switzerland, Viganello, Lugano, Switzerland; Oncology Hospital, Thun, Switzerland; SAKK Coordinating Center, Bern, Switzerland; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, University Hospital, Bern, Switzerland
| | - A. Schönenberger
- CEPO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Breast Center, Kantonspital, St. Gallen, Switzerland; Kantonsspital, Aarau, Switzerland; Oncology Institute of Southern Switzerland, Viganello, Lugano, Switzerland; Oncology Hospital, Thun, Switzerland; SAKK Coordinating Center, Bern, Switzerland; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, University Hospital, Bern, Switzerland
| | - O. Pagani
- CEPO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Breast Center, Kantonspital, St. Gallen, Switzerland; Kantonsspital, Aarau, Switzerland; Oncology Institute of Southern Switzerland, Viganello, Lugano, Switzerland; Oncology Hospital, Thun, Switzerland; SAKK Coordinating Center, Bern, Switzerland; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, University Hospital, Bern, Switzerland
| | - J. Lüthi
- CEPO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Breast Center, Kantonspital, St. Gallen, Switzerland; Kantonsspital, Aarau, Switzerland; Oncology Institute of Southern Switzerland, Viganello, Lugano, Switzerland; Oncology Hospital, Thun, Switzerland; SAKK Coordinating Center, Bern, Switzerland; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, University Hospital, Bern, Switzerland
| | - M. Simcock
- CEPO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Breast Center, Kantonspital, St. Gallen, Switzerland; Kantonsspital, Aarau, Switzerland; Oncology Institute of Southern Switzerland, Viganello, Lugano, Switzerland; Oncology Hospital, Thun, Switzerland; SAKK Coordinating Center, Bern, Switzerland; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, University Hospital, Bern, Switzerland
| | - A. Giobbie-Hurder
- CEPO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Breast Center, Kantonspital, St. Gallen, Switzerland; Kantonsspital, Aarau, Switzerland; Oncology Institute of Southern Switzerland, Viganello, Lugano, Switzerland; Oncology Hospital, Thun, Switzerland; SAKK Coordinating Center, Bern, Switzerland; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, University Hospital, Bern, Switzerland
| | - C. Genton
- CEPO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Breast Center, Kantonspital, St. Gallen, Switzerland; Kantonsspital, Aarau, Switzerland; Oncology Institute of Southern Switzerland, Viganello, Lugano, Switzerland; Oncology Hospital, Thun, Switzerland; SAKK Coordinating Center, Bern, Switzerland; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, University Hospital, Bern, Switzerland
| | - S. Aebi
- CEPO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Breast Center, Kantonspital, St. Gallen, Switzerland; Kantonsspital, Aarau, Switzerland; Oncology Institute of Southern Switzerland, Viganello, Lugano, Switzerland; Oncology Hospital, Thun, Switzerland; SAKK Coordinating Center, Bern, Switzerland; IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA; Medical Oncology, University Hospital, Bern, Switzerland
| |
Collapse
|
9
|
Böhlen B, Lüthi J, Guyer A. Neues Verfahren zur elektrostatischen Gasentstaubung. CHEM-ING-TECH 2004. [DOI: 10.1002/cite.330391506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|